Oligonucleotide Synthesis Companies

The global oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030 from USD 10.5 billion in 2025, at a CAGR of 18.6% during the forecast period.

The global oligonucleotide synthesis market is highly competitive, featuring companies like Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US). These market players have implemented several strategies, including product launches, acquisitions, agreements, collaborations, and expansions, to enhance their positions in the market.

Similarly, the prominent players in the oligonucleotide therapeutics market are Biogen (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland).

To know about the assumptions considered for the study download the pdf brochure

Danaher Corporation (US): One of the key players in the oligonucleotide synthesis market is Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, along with its sister company, Cytiva. Together, they offer a variety of products, including pre-designed and custom oligonucleotide probes, primers, and therapeutic oligonucleotides, such as antisense oligonucleotides (ASOs). Additionally, the company supplies reagents, consumables, and equipment, including synthesizers for oligonucleotide synthesis. Geographically, the company operates in over 50 countries spanning North America, the Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva have focused on organic growth strategies, emphasizing expansions and partnerships. For instance, in 2023, Integrated DNA Technologies opened a therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This state-of-the-art facility is designed to produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligonucleotides. The facility includes eight ISO cleanrooms, purification suites, chemical distribution & storage areas, quality control laboratories, analytical spaces for product testing, and ancillary & office spaces. There are also shell spaces set aside for future expansion.

Thermo Fisher Scientific (US): Thermo Fisher is one of the leading players in the oligonucleotide synthesis market in 2024. This significant share is due to a strong product portfolio, including custom & pre-designed primers, probes, DNA, RNA oligos, and reagents & consumables. The company undertakes various organic & inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific collaborated with the University of Sheffield to develop workflows to characterize and monitor complex oligonucleotide and mRNA products. The company also has a strong geographic presence and operates in over 50 countries across North America, Europe, the Asia Pacific, and Latin America.

Biogen (US): Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults, along with the growing adoption of Spinzara, a blockbuster oligonucleotide-based drug the company has offered since 2016, supports its leading position in the market. The company operates an oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is used to produce antisense oligonucleotide drugs like Spinzara and other candidates currently in development. It employs various strategies to strengthen its market presence, including expansions and collaborations. For instance, in February 2025, Biogen and Stoke Therapeutics, Inc. collaborated to develop & commercialize Zorevunersen, an investigational antisense oligonucleotide (ASO) for treating Dravet syndrome.

Market Ranking

Market competition is analyzed across two landscapes: oligonucleotide-based drugs and synthesized oligonucleotides. The market is highly consolidated for synthesized oligonucleotides, dominated by five key players who collectively hold approximately 50-60% of the total market share. Danaher Corporation (US) has a significant market share, reflecting its extensive influence through a diverse product portfolio. Thermo Fisher Scientific Inc. (US) accounted for the largest market share owing to its wide range of oligonucleotide products, including primers, probes, custom oligos, reagents, and custom oligo modifications. Merck KGaA (Germany), LGC Limited (UK), and Eurofins Scientific (Luxembourg) have also captured significant portions of the market by focusing on research and development to introduce innovative new products that strengthen their market presence. Growth opportunities in the Asia Pacific and Latin American markets also encourage these companies to enhance their presence in these regions.

Regional & emerging players hold the remaining 40-50% of the market, leading to significant consolidation. Several key factors contribute to the growth of this market, including technological advancements, product innovation, strategic partnerships, and the increasing demand from pharmaceutical & biopharmaceutical companies.

With respect to oligonucleotide-based drugs, the market is highly consolidated, with the top five players holding 85-90% of the market. Companies that account for most of the market include Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Novartis AG (Switzerland), Biogen (US), and Astellas Pharma Inc. (Japan). Several companies have successfully launched oligonucleotide-based drugs, catering to specific applications and steadily increasing their revenue. Their significant market share results from innovative, first-in-class product launches, strategic partnerships, and a rising demand for personalized medicine. Meanwhile, regional & emerging players account for the remaining 10-15% of the market.

Related Reports:

Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic (Rare Diseases), Research, Diagnostics) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com